Human interleukin-6
Also known as: B-cell stimulatory factor 2, BSF-2, BSF‑2, Hepatocyte-stimulating factor, IL-6, Interferon beta-2, Interleukin-6, Interleukin‑6
Source Human interleukin-6 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Human interleukin‑6 (IL‑6) is a pleiotropic cytokine that regulates immune, inflammatory and hematopoietic processes. It is produced by many cell types, notably bone‑marrow stromal cells, and circulates in the blood where it can act through membrane‑bound or soluble IL‑6 receptors. Research has linked IL‑6 to the pathogenesis of autoinflammatory conditions such as familial Mediterranean fever (FMF) and to the growth and survival of multiple myeloma (MM) plasma cells.
Mechanism of Action
IL‑6 binds to its specific IL‑6 receptor (IL‑6Rα), which then associates with the signaling subunit gp130. This complex triggers intracellular cascades including Janus kinase (JAK) activation, leading to STAT3 phosphorylation, as well as MAPK and PI3K‑AKT pathways. The resulting transcriptional program promotes acute‑phase protein production, B‑cell differentiation, and survival signals in malignant plasma cells.
What the Research Shows
A 1998 review documented extensive evidence that IL‑6 acts as a key autocrine and paracrine growth factor for multiple myeloma cells, with bone‑marrow stromal cells being the principal source of the cytokine in patients. Elevated soluble IL‑6R levels further amplify this signaling. A 2022 autoinflammatory disease review identified IL‑6 as the most discriminating cytokine during FMF attacks and noted an investigator‑initiated trial of the anti‑IL‑6R antibody tocilizumab in colchicine‑refractory FMF. A 2001 combinatorial protein‑design study described minibody variants and a cyclic peptide that inhibit IL‑6 in vitro, illustrating the feasibility of direct IL‑6 blockade. Collectively, these sources highlight IL‑6’s central role in disease mechanisms and the emerging strategies to modulate its activity.
Reported Benefits
Targeting the IL‑6 pathway has shown promise in preclinical models of multiple myeloma, where inhibition reduces tumor cell proliferation and survival. Early clinical investigation of anti‑IL‑6R antibodies (e.g., tocilizumab) suggests potential benefit for patients with refractory FMF, decreasing inflammatory attacks. Engineered IL‑6 inhibitors such as minibodies and cyclic peptides demonstrate in‑vitro capability to block IL‑6 signaling, offering a template for future therapeutic development.
Limitations of the Evidence
Evidence for IL‑6‑targeted therapies remains limited to early‑phase clinical trials (e.g., tocilizumab in FMF) and preclinical experiments; long‑term efficacy and safety have not been established. The reviewed minibody and peptide inhibitors have only been evaluated in vitro, with no reported animal or human data. Moreover, IL‑6’s broad physiological roles raise concerns that systemic blockade may impair host defense and normal hematopoiesis.
Safety Considerations
Because IL‑6 mediates acute‑phase and immune responses, its inhibition can predispose to infections, including opportunistic pathogens, and may cause neutropenia, elevated liver enzymes, and lipid abnormalities. In experimental settings, excess IL‑6 is associated with fever, hypotension and systemic inflammation, underscoring the need for careful monitoring when modulating this pathway.
How It Is Administered
Research‑grade IL‑6 protein and its inhibitors are typically delivered by intravenous or subcutaneous injection in experimental protocols. Formulations may include sterile aqueous solutions for injection; dosing regimens are defined by individual study designs rather than standardized clinical guidelines.
Routes of Administration
Goals & Uses
- B-cell and plasma cell differentiation (research)Immunology ResearchHigh
- Immune activationImmunologyModerate
- Hematopoiesis stimulationHematologyModerate
- Thrombocytopenia (chemotherapy-induced) mitigationHematologyLow
- Acute-phase response induction (research model)Research / ImmunologyHigh
- Hematopoiesis supportHematologyModerate
Contraindications
- Active systemic infection or sepsisInfectious DiseaseHigh
- Malignancy (IL-6-dependent tumors)OncologyHigh
- Severe inflammatory diseaseAutoimmuneHigh
- Active autoimmune diseaseAutoimmunityHigh
Adverse Effects
- Injection site reactionsLocalCommon
- AnemiaHematologicUncommonLow red blood cell count or hemoglobin
- HypotensionCardiovascularUncommonLow blood pressure
- Fever / flu-like syndromeSystemicCommon
- FeverSystemicCommonElevated body temperature
- ThrombocytosisHematologyCommon
- Fatigue and malaiseSystemicCommon
Drug Interactions
- CYP450-metabolized drugs (e.g., warfarin, cyclosporine)Moderate
- CorticosteroidsModerate
- Tocilizumab / Sarilumab (IL-6R antagonists)High
Population Constraints
- Pediatric populationsAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant or breastfeeding individualsReproductive SafetyRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trial material, not marketed
- United StatesInvestigationalInvestigational New Drug (IND) status for clinical trials only
- United KingdomUnapprovedNot approved by MHRA; research and investigational use only.
Recombinant human IL-6 itself is not an approved drug product in any major jurisdiction. It is used as a research reagent and has been investigated in early-phase trials (e.g., to counteract chemotherapy-induced thrombocytopenia) but development as a therapeutic has largely been superseded by IL-6 pathway antagonists.
Evidence & Sources
- Journal ArticleModerateVaughan CK, Sollazzo M2001-01-01T00:00:00.000000Z
- Journal ArticleModerateKawakami A, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateTreon SP, Anderson KC1998-01-01T00:00:00.000000Z
Frequently Asked Questions
What diseases are most closely linked to IL‑6 activity?
IL‑6 is strongly implicated in multiple myeloma, where it drives plasma‑cell growth, and in autoinflammatory disorders such as familial Mediterranean fever, where its levels rise during disease flares.
Are there approved drugs that target IL‑6?
While the IL‑6 protein itself is a research compound, monoclonal antibodies against the IL‑6 receptor (e.g., tocilizumab) have been investigated in clinical trials for FMF and are approved for other inflammatory conditions, but not specifically for IL‑6‑related research use.
How is IL‑6 inhibition achieved in the laboratory?
Laboratory approaches include engineered minibodies, cyclic peptides, and conventional antibodies that bind IL‑6 or its receptor, preventing the cytokine from initiating downstream signaling.
What are the main safety concerns with blocking IL‑6?
Blocking IL‑6 can reduce host defense against infections, cause neutropenia, liver enzyme elevations, and metabolic changes; monitoring for these adverse effects is essential in any trial.
Can IL‑6 be used as a biomarker for disease activity?
Yes, studies have shown that serum IL‑6 levels correlate with disease activity in FMF attacks and may reflect inflammatory burden in multiple myeloma, making it a potential biomarker in research settings.
What is Human interleukin-6?
Human interleukin‑6 (IL‑6) is a pleiotropic cytokine that regulates immune, inflammatory and hematopoietic processes. It is produced by many cell types, notably bone‑marrow stromal cells, and circulates in the blood where it can act through membrane‑bound or soluble IL‑6 receptors. Research has linked IL‑6 to the pathogenesis of autoinflammatory conditions such as familial Mediterranean fever (FMF) and to the growth and survival of multiple myeloma (MM) plasma cells.
What is Human interleukin-6 used for?
Human interleukin-6 is educationally associated with: B-cell and plasma cell differentiation (research), Immune activation, Hematopoiesis stimulation, Thrombocytopenia (chemotherapy-induced) mitigation, Acute-phase response induction (research model), Hematopoiesis support. Educational only — not medical advice.
How is Human interleukin-6 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Human interleukin-6?
Reported adverse effects include: Injection site reactions, Anemia, Hypotension, Fever / flu-like syndrome, Fever, Thrombocytosis, Fatigue and malaise. This list is not exhaustive — consult a qualified clinician.
Who should avoid Human interleukin-6?
Recorded contraindications: Active systemic infection or sepsis, Malignancy (IL-6-dependent tumors), Severe inflammatory disease, Active autoimmune disease. Consult a qualified clinician before use.